8-K: Marizyme Secures $1.25 Million Loan from Qualigen Therapeutics

Marizyme, Inc. has entered into a promissory note agreement with Qualigen Therapeutics, Inc., securing a $1.25 million loan with an 18% annual interest rate.

Summary

• Marizyme, Inc. has borrowed $1,250,000 from Qualigen Therapeutics, Inc. through a promissory note.
• The loan has an annual interest rate of 18%.
• The principal and interest are due upon demand by the lender.
• Marizyme can prepay the loan at any time without penalty.
• In case of default, Qualigen Therapeutics will have liquidation preference and first right of recovery in any bankruptcy or insolvency proceedings.

Sentiment

Score: 4

Explanation: The high interest rate and on-demand repayment terms suggest a potentially precarious financial situation for Marizyme, despite securing the loan. The liquidation preference for the lender also adds a negative aspect.

Positives

• Marizyme has secured $1,250,000 in funding.
• The loan can be prepaid at any time without penalty, providing flexibility.

Negatives

• The loan has a high interest rate of 18%.
• The loan is payable on demand, which could create uncertainty for Marizyme.
• Qualigen Therapeutics has liquidation preference in case of default, which could be detrimental to other creditors.

Risks

• The high interest rate of 18% could strain Marizyme's finances.
• The demand repayment clause creates uncertainty and potential liquidity risk.
• The liquidation preference for Qualigen Therapeutics could negatively impact other creditors in case of financial distress.

Management Comments

• David Barthel, CEO of Marizyme, signed the promissory note on behalf of the company.

Industry Context

This type of financing is common for companies seeking short-term capital, especially in the biotechnology sector where funding needs can be immediate and variable. The high interest rate suggests that Marizyme may have limited access to lower-cost capital.

Comparison to Industry Standards

• An 18% interest rate is high compared to typical bank loans, suggesting Marizyme may have limited access to traditional financing.
• Companies with strong credit ratings often secure loans at much lower rates, sometimes in the single digits.
• The on-demand repayment clause is less common in standard term loans and indicates a higher risk for the lender.

Stakeholder Impact

• Shareholders may be concerned about the high interest rate and the potential impact on the company's financial stability.
• Creditors may be concerned about the liquidation preference given to Qualigen Therapeutics.
• Employees may be indirectly affected by the company's financial health.

Key Dates

Keywords

Promissory Note, Loan, Debt Financing, Interest Rate, Liquidation Preference, Marizyme, Qualigen Therapeutics